AC BioScience SA -

AC BioScience is bringing into clinical trial two ground-breaking tumor conditioning drugs that potentiate immuno and chemo therapies to treat resistant and hypoxic cancers. Lead molecule ACB1801 restores tumor antigen presentation by inducing deep phenotypic changes thus potentiating ant-PD1 ICI efficacy through recruitment of effector immune cells. Our second molecule ACB2003.3 is a first-in-man angiogenic therapy that increases efficacy of gold standard cytotoxic treatments. We develop drug candidates to PoC clinical Phase II results and then monetize the innovation through out licensing with major pharmas. Our molecules target large market potential across a broad range of cancers. Our company is the recipient of multiple EU and Innosuisse grants in support of our innovations.